Rituximab biosimilar (Biocad)

利妥昔单抗生物类似药 (Biocad)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRituximab biosimilar (Biocad)
Drug Alias Name利妥昔单抗生物仿制药 (Biocad)AcellbiaBCD-020
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsArthritis, RheumatoidLymphoma, FollicularLymphoma, B-Cell, Marginal Zone +[6] 
Global Approved IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryRussian Federation
Original Approved Date2015/01/01
Country/TerritoryUkraineRussian FederationSouth Africa +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBIOCAD JSC
China Registration ClassN/A

Develop Information

Active CompaniesBIOCAD JSC
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsArthritis, RheumatoidLymphoma, FollicularLymphoma, B-Cell, Marginal Zone +[4] 

Other Information

ATC CodeL01XC02
Related LinksN/A